Advertisement
Canada markets closed

  • S&P/TSX

    22,259.16
    -31.46 (-0.14%)
     

  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     

  • DOW

    39,056.39
    +172.13 (+0.44%)
     

  • CAD/USD

    0.7284
    -0.0003 (-0.04%)
     

  • CRUDE OIL

    79.18
    +0.80 (+1.02%)
     

  • Bitcoin CAD

    85,002.68
    -1,695.34 (-1.96%)
     

  • CMC Crypto 200

    1,320.40
    +25.72 (+1.99%)
     

  • GOLD FUTURES

    2,316.20
    -8.00 (-0.34%)
     

  • RUSSELL 2000

    2,055.14
    -9.51 (-0.46%)
     

  • 10-Yr Bond

    4.4920
    +0.0290 (+0.65%)
     

  • NASDAQ

    16,302.76
    -29.80 (-0.18%)
     

  • VOLATILITY

    13.01
    -0.22 (-1.66%)
     

  • FTSE

    8,354.05
    +40.38 (+0.49%)
     

  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     

  • CAD/EUR

    0.6774
    +0.0003 (+0.04%)
     
MARKETS LIVE BLOG:

DOW POSTS 6TH DAY OF GAINS BUT NASDAQ SLIPS

Fed's Collins warns interest rates will likely stay higher for longer

Analysts Are Bullish on Verastem in September

Daniel Collins
Updated
Analysts Are Bullish on Verastem in September

On September 11, Verastem (VSTM) stock closed at $9.17, which is ~13% below its 52-week high of $10.35 on September 4. On September 6, Verastem announced that the company completed dosing the first patient with duvelisib and venetoclax combination therapy for the multicenter phase 1/2 trial at the Dana-Farber Cancer Center. Verastem is evaluating the safety and efficacy of duvelisib and venetoclax combination therapy for the treatment of individuals with relapsed or refractory chronic lymphoblastic leukemia or small lymphocytic lymphoma.

Continue reading